All News
Filter News
Found 808,982 articles
-
Patent Issued to IRISYS, LLC for a New Liposomal Anticancer Drug Delivery System
6/18/2021
IRISYS, LLC announced today that it has been issued U.S. Patent No. 11,033,530, Liposomal Anticancer Compositions.
-
ADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma
6/18/2021
ADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16 th Annual International Conference on Malignant Lymphoma
-
G1 Therapeutics Announces Addition of Alicia Secor to Board of Directors
6/18/2021
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Alicia Secor to its Board of Directors
-
The Food and Drug Administration (FDA) grants a Breakthrough Device Designation to the MIScoli an innovative vertebral body tethering device to treat idiopathic scoliosis
6/18/2021
Spinologics Inc. / Spino Modulation Inc., a subsidiary of Spinologics Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted the company a Breakthrough Device Designation for its MIScoli™ system, an innovative vertebral body tethering (VBT) device to treat scoliosis in young adolescents.
-
TG Therapeutics Announces Preclinical and Clinical Data Evaluating TG-1701 at the 16th International Congress on Malignant Lymphoma
6/18/2021
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from two presentations evaluating TG-1701, the Company’s investigational once-daily, oral BTK inhibitor, presented today during the 16 th International Congress on Malignant Lymphoma (ICML).
-
Moderna Reaffirms Commitment to Job Creation in Massachusetts
6/18/2021
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, reaffirmed its commitment to job creation in Massachusetts.
-
Predictmedix Inc. Files Registration Statement on Form 20-F With the SEC
6/18/2021
Predictmedix Inc. announced today that it has filed a registration statement on Form 20-F to register its common shares with the United States Securities and Exchange Commission (the “SEC”).
-
Natera Awarded Advanced Diagnostic Laboratory Test (ADLT) Status for its Signatera® MRD Test From CMS
6/18/2021
Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted ADLT status for the Signatera molecular residual disease (MRD) test.
-
Cureduchenne Launches Next-generation Data-sharing Platform To Accelerate A Cure For Duchenne And Becker Muscular Dystrophy
6/18/2021
CureDuchenne announces the launch of CureDuchenne Link , a centralized data hub that puts individuals with Duchenne and Becker firmly at the center of research.
-
Iveric Bio to Present Zimura® GATHER2 Enrollment and Retention Updates and New GATHER1 Post-Hoc Analyses Today at its Dry Age-Related Macular Degeneration Virtual Symposium for Investors
6/18/2021
IVERIC bio, Inc. announced that at the Company’s Virtual Symposium for Investors and Analysts, Arshad M. Khanani, MD, MA, of Sierra Eye Associates and Chairman of the GATHER2 Steering Committee, will discuss an accelerated enrollment timeline and patient retention, including injection fidelity, for GATHER2, the Company’s pivotal clinical trial of Zimura® in development for the treatment of geographic atrophy secondary to age-related macular degeneration.
-
Bioelectronica® Corporation Wins Annual CYTO Virtual Interactive 2021 Innovation Showcase
6/18/2021
Bioelectronica ® Corporation announced today that the company won the Innovation Showcase competition that was held at CYTO Virtual Interactive 2021.
-
RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
6/18/2021
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the closing of its previously announced underwritten public offering of 4,356,060 shares of its common stock at a price to the public of $33.00 per share
-
Bristol Myers Squibb Receives European Commission Approval for Onureg® (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia
6/18/2021
Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has granted full Marketing Authorization for Onureg® (azacitidine tablets) as a maintenance therapy in adult patients with acute myeloid leukemia
-
Avanos Medical, Inc. to Present at the 2021 Raymond James Human Health Innovation Conference
6/18/2021
Avanos Medical, Inc. announced that Joe Woody, chief executive officer, will present and participate in an analyst-led fireside chat at the Virtual 2021 Raymond James Human Health Innovation Conference Tues., June 22 at approximately 10:40 a.m., ET.
-
Aditxt Announces the Appointment of Dr. Lauren Chung to its Board of Directors
6/18/2021
Aditx Therapeutics, Inc. announced today that Dr. Lauren Chung will join the Aditxt board of directors as an independent director.
-
Predictive Oncology Announces Closing of $21.34 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
6/18/2021
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has completed the closing of its previously announced registered direct offering of 15,520,911 shares of its common stock and warrants
-
Praetego Inc Awarded New NIH Funding to Investigate Novel Small Molecule Drug Candidates for Neurodegeneration and Alzheimer's Disease.
6/18/2021
Praetego Inc (https://www.praetego.com/), a pharmaceutical company committed to improving health outcomes for patients living with diabetes, is pleased to announce a $0.46M funding award from the National Institutes of Health.
-
Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress
6/18/2021
Scholar Rock today announced an oral e-presentation of clinical results from the TOPAZ Phase 2 trial.
-
European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis
6/18/2021
The European Commission (EC) has approved Aubagio® (teriflunomide) for the treatment of pediatric patients 10 to 17 years of age with relapsing-remitting multiple sclerosis (RRMS).
-
Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies
6/18/2021
Nuevocor, a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, has announced the completion of an oversubscribed $24 million Series A financing round.